- Regulatory Status
- RUO
- Other Names
- B-lymphocyte antigen CD19, CD19 Molecule, CD19 Antigen, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, CVID3
-
When recombinant human CD19-Fc Chimera is immobilized at 2 µg/mL, biotinylated recombinant human CD81 binds in a dose-dependent manner. The EC50 range for this effect is 100 - 400 ng/mL. -
Stability testing for recombinant human CD19-Fc Chimera. Recombinant human CD19-Fc Chimera was aliquoted in PBS at 0.2 mg/mL. One aliquot was frozen and thawed four times (4x Freeze/Thaw), and compared to a control kept at 4°C (Control). The samples were tested in a binding assay with biotinylated recombinant human CD81.
| Cat # | Size | Price | Quantity Check Availability | ||
|---|---|---|---|---|---|
| 789002 | 10 µg | $94.00 | |||
| 789004 | 25 µg | $229.00 | |||
| 789006 | 100 µg | $581.00 | |||
CD19 is a 95 kD transmembrane glycoprotein that functions as a co-receptor for the B-cell antigen receptor (BCR) complex on B lymphocytes. CD19 is expressed throughout B cell development, and it is commonly used as a B-cell lineage marker. CD19 plays an important role in B-cell activation and humoral immune responses. It is required for the responsiveness of mature B cells to antigen stimulation, germinal center development, and antibody affinity maturation. CD19's association with the BCR, CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu13 enables CD19 to amplify B-cell signaling and decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. CD19 activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca2+ stores. CD19 polymorphisms are associated with the development of autoimmunity by promoting autoantibody production. Homozygous mutations in CD19 cause a type of hypogammaglobulinemia in which the response of mature B cells to antigenic stimulation is defective.
Product Details
- Source
- Human CD19, amino acid Glu21-Lys291 (Accession # P15391) with a C-terminal IgG1 Fc and 6-His tag was expressed in CHO.
- Molecular Mass
- The 515 amino acid recombinant protein has a predicted molecular mass of approximately 57.5 kD. The DTT-reduced protein migrates at approximately 75 kD and the non-reduced protein migrate at approximately 150 kD by SDS-PAGE. The predicted N-terminal amino acid is Glu.
- Purity
- >95%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.22 µm filtered protein solution is in PBS
- Endotoxin Level
- Less than 0.1 EU per µg protein as determined by the LAL method.
- Concentration
- 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- When recombinant human CD19-Fc Chimera is immobilized at 2 µg/mL, biotinylated human CD81-Fc Chimera binds in a dose-dependent manner. The EC50 range for this effect is 100 - 400 ng/mL. HRP Avidin (Cat. No. 405103) was used to detect the binding.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
- Product Citations
-
Antigen Details
- Structure
- Covalently linked homodimer
- Distribution
-
Detected on marginal zone and germinal center B cells in lymph nodes, detected on blood B cells
- Function
- Functions as a co-receptor for the B-cell antigen receptor (BCR) complex on B lymphocytes
- Interaction
- B cell
- Ligand/Receptor
- CD21, CD81
- Bioactivity
- Measured by its ability to bind human CD81
- Cell Type
- B cells
- Biology Area
- Adaptive Immunity, Immuno-Oncology, Immunology
- Molecular Family
- Soluble Receptors
- Antigen References
-
- de Rie MA, et al. 1989. Cell Immunol. 118:368-81.
- Carter RH, et al. 1992. Science. 256:105-107.
- Buhl AM, et al. 1997. J Exp Med. 186:1897-910.
- Sato S, et al. 1997. J Immunol. 159:3278-87.
- Wang Y, et al. 2002. Immunity. 17:501-14.
- van Zelm MC, et al. 2006. N Engl J Med. 354:1901-12.
- Gene ID
- 930 View all products for this Gene ID
- UniProt
- View information about CD19 on UniProt.org